Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer.
O'Donnell CDJ, Naleid N, Siripoon T, Zablonski KG, Storandt MH, Selfridge JE, Hallemeier CL, Conces ML, Jethwa KR, Bajor DL, Thiels CA, Warner SG, Starlinger PP, Atwell TD, Mitchell JL, Mahipal A, Jin Z. O'Donnell CDJ, et al. Among authors: bajor dl. Cancers (Basel). 2024 Jun 29;16(13):2407. doi: 10.3390/cancers16132407. Cancers (Basel). 2024. PMID: 39001469 Free PMC article.
Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
Hue JJ, Dorth J, Sugumar K, Hardacre JM, Ammori JB, Rothermel LD, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Hue JJ, et al. Am Surg. 2021 Sep;87(9):1386-1395. doi: 10.1177/00031348211038581. Epub 2021 Aug 12. Am Surg. 2021. PMID: 34382877
Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma.
Sugumar K, Hue JJ, Hardacre JM, Ammori JB, Rothermel LD, Dorth J, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Sugumar K, et al. HPB (Oxford). 2022 Apr;24(4):433-442. doi: 10.1016/j.hpb.2021.08.938. Epub 2021 Aug 18. HPB (Oxford). 2022. PMID: 34465529 Free article.
A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.
Elshami M, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge JE, Chavin KD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Elshami M, et al. HPB (Oxford). 2022 Aug;24(8):1280-1290. doi: 10.1016/j.hpb.2021.12.022. Epub 2022 Jan 6. HPB (Oxford). 2022. PMID: 35063353 Free article.
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Otegbeye F, Cooper B, Caimi P, Zamborsky K, Reese-Koc J, Hillian A, Hernandez-Collazo Y, Lee G, Boughan K, Tomlinson B, Gallogly M, Metheny L, Bajor D, Selfridge J, Saltzman J, Lazarus H, de Lima M, Wald D. Otegbeye F, et al. Transplant Cell Ther. 2022 May;28(5):250.e1-250.e8. doi: 10.1016/j.jtct.2022.02.008. Epub 2022 Feb 14. Transplant Cell Ther. 2022. PMID: 35172204 Free PMC article. Clinical Trial.
54 results